Novel method to measure glomerular filtration rate

测量肾小球滤过率的新方法

• 批准号: 6926210
• 负责人: CHRISTOPHER P REINHARDT
• 金额: $ 35.23万
• 依托单位: BIOPAL, INC
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-08-01 至 2007-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6926210
• 关键词: activation analysis; analytical method; biological signal transduction; biomarker; electromagnetic radiation; glomerular filtration rate; kidney circulation; laboratory rabbit; measurement; method development; serology /serodiagnosis; stable isotope; urinalysis

DESCRIPTION (provided by applicant): The hypothesis tested during Phase I was that an ideal filtration marker can be labeled with a metal that when neutron activated generates a strong photon signal suitable for the measurement of glomerular filtration rate (GFR). We successfully proved our hypothesis and demonstrated concept feasibility. The results of our Phase I study have identified three promising agents. Our Phase II research will expand on this work by directly comparing our novel method to traditional methods of measuring GFR (sodium iothalanate (I-125) and 51-Cr-EDTA) using an in vivo rabbit model. In addition, Phase II will evaluate the biodistribution of each agent and will initiate preclinical toxicology studies necessary to carry the project forward to Phase lIl. Our goal is to identify an ideal filtration marker that can be labeled with two different stable isotopes. As a result, we can provide a non-radioactive GFR assay kit that is safe, easy-to-use, accurate, and cost-effective, while providing a diagnostic modality that is versatile for a wide range of clinical and research applications.

描述（由申请人提供）： 在阶段I期间测试的假设是，理想的滤过标记物可以用金属标记，当中子激活时，该金属产生适合于测量肾小球滤过率（GFR）的强光子信号。我们成功地证明了我们的假设，并证明了概念的可行性。我们的I期研究结果确定了三种有前途的药物。我们的II期研究将通过直接比较我们的新方法与使用体内兔模型测量GFR（碘化钠（I-125）和51-Cr-EDTA）的传统方法来扩展这项工作。此外，II期将评估每种药剂的生物分布，并将启动将项目推进至III期所需的临床前毒理学研究。我们的目标是确定一个理想的过滤标记，可以用两种不同的稳定同位素标记。因此，我们可以提供一种安全、易于使用、准确和具有成本效益的非放射性GFR测定试剂盒，同时提供一种适用于广泛临床和研究应用的诊断模式。